Latest Us Market News

OD6 Metals has secured a strategic foothold in the US critical minerals market by acquiring the Quinn Fluorspar Project in Nevada, delivering ultra-high-grade assay results and commencing systematic exploration. Meanwhile, metallurgical progress at its Splinter Rock rare earths project and new copper targets at Gulf Creek underpin a diversified critical minerals portfolio.

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Janus Electric has unveiled a comprehensive growth strategy targeting over 1,600 electrified heavy trucks by FY29, leveraging its unique retrofit and battery swap technology across multiple international markets.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Zip Co reported a 41.5% jump in third quarter cash EBTDA to $65.1 million, driven by accelerated US transaction volume growth of 43.1% and steady credit losses. The company upgraded its FY26 cash EBTDA guidance to at least $260 million, highlighting robust profitability and expanding customer engagement.

Carbonxt Group has secured $750,000 through convertible notes from major shareholder Phelbe Pty Ltd, targeting expansion of its Minnesota pellet manufacturing and increasing its New Carbon Processing stake to 48.1%.

Iondrive Limited has confirmed over 90% extraction of key rare earth elements neodymium and praseodymium from US commercial samples, exceeding prior economic assumptions and advancing its modular recycling technology toward commercial deployment.

Botanix Pharmaceuticals has agreed to terms with Piramal to establish an alternate supplier for the active ingredient in Sofdra, aiming to reduce costs by up to 40% and strengthen its supply chain.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.